January - September 2009 interim report from Biotage

Biotage AB (STO:BIOTA):

Third quarter 2009
• Net sales decreased by 2 percent to 90.6 MSEK (92.3). At comparable exchange rates sales decreased by 13 percent.
• The operating result amounted to 2.0 MSEK (7.0).
• The result after tax amounted to 1.4 MSEK (6.6).
• Earnings per share amounted to 0.01 SEK (0.14).
• Net cash at September 30, 2009 amounted to 326.6 MSEK.
• As a part of Biotage’s buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK, i.e. an average share price of 6.93 SEK.
• The cash flow from operating activities amounted to 4.5 MSEK (13.0).

January - September 2009
• Net sales increased by 7 percent to 294.6 MSEK (276.3). At comparable exchange rates sales decreased by 11 percent.
• The operating result amounted to -13.7 MSEK (10.8). Before restructuring costs the operating result amounted to 7.5 MSEK (10.8).
• The result after tax amounted to -14.5 MSEK (8.8).
• Earnings per share amounted to -0.16 SEK (0.38).
• Net cash at September 30, 2009 amounted to 326.6 MSEK.
• Dividends to shareholders have been paid to the amount of 17.7 MSEK.
• As a part of Biotage’s buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK.
• The cash flow from operating activities amounted to 21.2 MSEK (10.2).

Source:

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.